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Assessment of iron sucrose use at a community-based hospital
Ada S. Jalice, BSHS, PharmD; Mercedes Frías, PharmD; Yarelys Garcia, BSN, PharmD
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BACKGROUND

RESULTS

RESULTS

• According to the World Health Organization, two billion people (30% of the
world’s population) suffer from anemia.1 Iron deficiency is the primary
causative factor in half of these cases.
• The standard of care for iron deficiency anemia is oral iron
supplementation as it is safe, effective, well tolerated, and inexpensive. 2

Male
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• Parenteral iron therapy is more costly and may cause severe side effects,
such as hypotension and anaphylaxis.3 It is indicated as first line in patients
who are unable to tolerate or absorb oral preparations, in those with
unresolved bleeding, in those undergoing dialysis, and in pregnant women.

Mean (years)

• Within our hospital system, an algorithm has been proposed to limit the first
line use of intravenous (IV) iron sucrose (Venofer®) .

OBJECTIVES
1. Determine if patients treated with Venofer® as first line therapy for iron
replacement met Baptist Health South Florida (BHSF)’s proposed IV iron
algorithm criteria
2. Assess if patients had hemoglobin, transferrin saturation (TSAT), and
ferritin levels drawn at baseline
3. Examine potential cost savings associated with proposed algorithm

Demographics
N=50
Gender
21 (42%)
29 (58%)
Age
58

Analysis of Inadequate Venofer® Therapy
n=16 (32%)
Total
Doses administered
36
Milligrams administered
10,700
Potential Cost Savings
Total cost
$3,168

Baseline Laboratory Parameters

DISCUSSION

N=50
Hemoglobin

50 (100%)

TSAT

18 (36%)

Ferritin

23 (46%)

• Out of 50 patients reviewed, 16 (32%) did not fall into the proposed patient
types who may receive IV iron first line.
• All patients had a baseline hemoglobin level (100%), 18 (36%) had
baseline TSAT values, and 23 (46%) had baseline ferritin levels.

Percent of Patients Meeting Baseline Laboratory Criteria Outlined in Algorithm
(N=50)
100

• On average, inappropriate therapy lasted about 2 days.

100%
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• Based on our facility’s acquisition cost of $29.61 for one 100 mg vial of
Venofer®, the cost of inappropriate parenteral therapy totaled $3,168.
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• Limitations: Brief study period, small sample size, evaluation of only
inpatients, and retrospective data collection that depended on what was
documented in the electronic medical record.
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METHODOLOGY

% patients 50
40

42%
34%
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• This retrospective study was approved by the BHSF Institutional Review
Board.

0
Baseline hemoglobin <12 g/dL

Baseline TSAT <30%

Baseline ferritin <1200 ng/mL

• Patients <18 years old and those who first received oral iron
supplementation were excluded.
• Of the resultant records, fifty charts were chosen at random to determine if
they met the following criteria outlined in BHSF’s proposed algorithm:

Percent of Patient Types Outlined in Algorithm
(N=50)

o Baseline hemoglobin <12 g/dL, TSAT <30%, ferritin <1200 ng/mL
o Patient types:
-Dialysis
-Pregnant women

CONCLUSIONS
• The criteria outlined in our hospital system’s proposed algorithm can greatly
streamline the use of parenteral iron therapy.
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• An electronic report of all inpatients who received Venofer® in June 2016
was generated by our pharmacy systems specialist.

• All baseline hemoglobin levels were <12 g/dL (100%). However, only 17
patients (34%) had baseline TSAT <30% and only 21 patients (42%) had
baseline ferritin <1200 ng/mL.

None
32%

-Gastric surgery

Severe/ongoing
blood loss
34%

-Patients with gastrointestinal (GI) disorders

• Since these implications translate into safe and cost effective treatment, a
system wide initiative will be implemented to promote the use of oral iron
supplementation.
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DISCLOSURES

-Patients with malabsorption syndromes
-Patients with severe/ongoing blood loss
-Patients who cannot receive oral intake (NPO)
• For patients who did not meet the above criteria, the total cost of Venofer®
doses was calculated.

NPO
6%
Dialysis
8%
GI disorder
4%

Pregnant
16%
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